Form 10-K for the Fiscal Year Ended December 30, 2022
You state on page 46 that “[a]ny mark-up on reimbursable expenses is included in revenues before reimbursements.” Please tell us how you determined that excluding the reimbursable expenses from the denominator of your “EBITDA as a % of revenues before reimbursements” calculation does not result in an individually tailored revenue recognition.Rest of the question
Refer to Question 100.04 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.
We acknowledge the Staff’s comment and respectfully advise the Staff that we believe our presentation of EBITDA as a % of revenues before reimbursements does not result in an individually tailored recognition and measurement principle that causes the presentation of non-GAAP measures to be misleading. The mark up on reimbursable expenses described on page 46 of the Form 10-K is a service fee that we charge our clients to cover the costs and risks associated with processing reimbursable expenses on behalf of our clients.Read in the replyRest of the answer
The costs being covered by this service fee include legal, contracting, purchasing, insurance, accounts payable, billing, and collections. While these costs are incurred in relation to the reimbursable expenses, they are not reimbursable expenses. Actual reimbursable expenses are excluded from both EBITDA (the denominator) and revenue before reimbursements (the numerator) in our presentation of EBITDA as a % of revenues before reimbursements. All the costs associated with processing and collecting reimbursable expenses are included in EBITDA. Revenue for this service fee is recognized as the services are being performed and therefore no adjustments are being made to our revenue recognition. Therefore, we believe that including this service fee in the denominator (revenue before reimbursements) of our EBITDA as a percentage of revenue before reimbursements is appropriate and does not result in an individually tailored recognition and measurement principle that causes the presentation of non-GAAP measures to be misleading.
First report after the company's reply of Oct 30, 2023: 10-Q filed Nov 3, 2023 ↗, against the 10-Q filed Aug 7, 2023 ↗.
Tickdelta does not hold the text of both reports, so they are not compared here.
You provide a range of forward-looking EBITDA as a % of revenues before reimbursements, a non-GAAP financial measure, for the third quarter of fiscal year 2023 and full fiscal year 2023. Please provide a reconciliation to the most directly comparable GAAP financial measure or a statement that providing such reconciliation requires unreasonable efforts.Rest of the question
Refer to Item 10(e)(1)(i)(B) of Regulation S-K and Question 102.10(b) of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.
We acknowledge the Staff’s comment and [included in our earnings release dated October 26th, 2023 and] will include, in all future filings that provide forward-looking guidance, a statement that providing a reconciliation of forward-looking EBITDA as a % of revenues before reimbursements to the most directly comparable GAAP financial measure, net income, requires unreasonable efforts.Read in the reply
First report after the company's reply of Oct 30, 2023: 10-Q filed Nov 3, 2023 ↗, against the 10-Q filed Aug 7, 2023 ↗.
Tickdelta does not hold the text of both reports, so they are not compared here.
We note your response to prior comment 1. It appears to us that you present “EBITDA as a % of revenues before reimbursements” ratio based on revenues before reimbursements as opposed to total revenues. Please tell us how presenting this measure as though you are an agent in these revenue generating transactions when gross presentation as a principal is required by GAAP does not represent an individually tailoredRest of the question
revenue recognition method. Refer to Question 100.04 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.
We acknowledge the Staff’s comment and respectfully advise the Staff that we believe our presentation of EBITDA as a percentage of revenues before reimbursements does not result in an individually tailored recognition and measurement method that causes the presentation of non-GAAP measures to be misleading.Read in the reply
Question 100.04 relates to “non-GAAP adjustments that have the effect of changing the recognition and measurement principles required to be applied in accordance with GAAP.” Our calculation of EBITDA as a percentage of revenue before reimbursements does not represent a substitute forRest of the answer
amounts recognized and measured over time on an accrual basis in accordance with GAAP and our accounting policies and methods. The calculation also does not have the effect of changing the pattern of revenue recognition.
On our consolidated statement of net income, we present revenues in accordance with GAAP, showing both components: (i) revenues before reimbursements and (ii) reimbursements.
Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third-party costs such as the cost of materials and certain subcontracts, are included as a component of revenues, and an equivalent amount of reimbursable expenses are included as a component of operating expenses. In addition, changes in the reimbursements component of revenues are not indicative of growth or decline in our business due to the variability of the travel and other out-of-pocket expenses included in this component of revenue. We believe that EBITDA as a percentage of total revenues would not provide a meaningful measure of profitability due to (i) the offsetting nature of reimbursements being included in revenues with a corresponding and identical expense and (ii) the variability in the reimbursements component of revenues.
The revenues before reimbursements component of revenues is used by management to evaluate financial results, develop budgets, and determine employee compensation. This component of revenue is the most meaningful metric to measure the growth or decline in our business, as the reimbursement component of revenues is not indicative of growth or decline of our business. Management provides guidance to investors regarding our growth in revenue before reimbursements which provides a meaningful comparison of past, present, and future operating results. EBITDA as a percentage of revenue before reimbursements is used by management, analysts, and investors to evaluate the profitability of the business. This metric is also one of the metrics used to determine CEO compensation.
Accordingly, we believe that presenting EBITDA as a percentage of revenue before reimbursements, when viewed in combination with our revenues calculated in accordance with GAAP, provides investors with a more complete and useful presentation of our financial performance. Given the reasons discussed above and our consistent presentation of EBITDA as a percentage of revenue before reimbursements in the past, we do not believe that the presentation is misleading to investors.
First report after the company's reply of Nov 20, 2023: 10-K filed Feb 23, 2024 ↗, against the 10-K filed Feb 24, 2023 ↗.
Tickdelta does not hold the text of both reports, so they are not compared here.
Also in this review: closing letter, 2024-01-10